All News

Uptake of PrEP has been slow, particularly among at-risk individuals between 13-19 years of age ar risk for HIV infection.

Atezolizumab (Tecentriq) approved in combination with bevacizumab (Avastin) for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.

Pharmacy Times® spoke with Jennifer Craig, PharmD, CSP, about Skin Cancer Awareness Month and the importance of skin care.

The researchers looked into the lifestyle habits of 6000 participants and found that individuals who consumed food rich in vitamin E had a decreased risk of a memory-robbing condition.

Officials from the FDA have approved flortaucipir F18 (Tauvid, Eli Lilly) for intravenous injection as the first drug used to help image a distinctive characteristic of Alzheimer disease in the brain called tau pathology.

A new law approved in Minnesota this week expands pharmacists’ authority by allowing them to administer FDA-authorized COVID-19 or SARS-CoV-2 vaccines when they become available.

Artificial intelligence will inevitably play a major role in hub services, improving efficiency and speed to therapy.

Top news of the week from Pharmacy Times®.

What drug was the first antibiotic used by doctors?

FDA has granted Fast Track designation to Cardiff Oncology’s onvansertib, an oral and highly-selective Polo-like Kinase 1 (PLK1) inhibitor, for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer.

Pharma companies that shift their attention to what providers, payers, and patients are asking for will profit from the growing worldwide market on preventative care.

Today, we’re celebrating the work of Dan McCoy, PharmD, a pharmacist at CVS in Madison, Wisconsin.

The second annual States Forum on Pharmacist Birth Control Services recently was held by the Birth Control Pharmacist project in partnership with the National Alliance of State Pharmacy Associations (NASPA).

In an era of high-priced drugs, health care stakeholders continue to explore alternative pricing models that focus on the concept of value-based drug purchasing models.